欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2021, Vol. 26 ›› Issue (9): 1048-1052.doi: 10.12092/j.issn.1009-2501.2021.09.011

• 药物治疗学 • 上一篇    下一篇

依折麦布联合他汀对急性冠脉综合征行急诊介入患者残粒脂蛋白胆固醇及MACE影响的临床研究

邓毅凡1,2,何胜虎2,王大新2,戴承晔2,3,徐笑挺2,3,张晶2   

  1. 1扬州大学医学院,扬州 225001,江苏;2扬州大学临床医学院,江苏省苏北人民医院心内科,扬州 225001,江苏;3大连医科大学,大连 116000,辽宁

  • 收稿日期:2021-07-09 修回日期:2021-08-23 出版日期:2021-09-26 发布日期:2021-09-30
  • 通讯作者: 张晶,男,博士,副主任医师,研究生导师,研究方向:冠心病防治。 E-mail: zhangjingyjs@163.com
  • 作者简介:邓毅凡,男,研究生在读,研究方向:冠心病防治。 E-mail: 13797847930@163.com
  • 基金资助:
    江苏省卫生健康委科研课题(Z2018032);扬州市重点研发(社会发展)项目(YZ2020103)

Clinical study of effect of ezetimibe combined with statins on residual lipoprotein cholesterol and MACE events in patients undergoing emergency intervention with acute coronary syndrome

DENG Yifan 1,2, HE Shenghu 2, WANG Daxin 2, DAI Chengye 2,3, XU Xiaoting 2,3, ZHANG Jing 2   

  1. 1 Medical College of Yangzhou University, Yangzhou 225001, Jiangsu, China; 2 Department of Cardiovascular Medicine, Clinical Medical College of Yangzhou University, Subei People's Hospital of Jiangsu Province, Yangzhou 225001, Jiangsu, China; 3 Dalian Medical University, Shenyang 116000, Dalian, Liaoning, China 
  • Received:2021-07-09 Revised:2021-08-23 Online:2021-09-26 Published:2021-09-30

摘要: 目的:研究依折麦布联合他汀对急性冠脉综合征(ACS)行急诊介入术(PCI)后患者残粒样脂蛋白-胆固醇(RLP-C)水平及主要心血管不良事件(MACE)的影响。方法:选取入院诊断ACS并行急诊PCI患者共90人,术后常规冠心病二级预防用药,将其随机分为两组,对照组48例服用阿托伐他汀,研究组42例加用依折麦布治疗,检测治疗前后RLP-C水平,并通过定期随访获取患者治疗期间MACE及药物不良反应。结果:与对照组相比,研究组治疗后RLP-C水平明显下降(P<0.05),MACE发生率明显降低(P<0.05),药物不良反应没有增加。结论:依折麦布联合他汀治疗可以降低ACS行急诊PCI术后患者RLP-C水平,减少MACE,不良反应少,值得推广应用。

关键词: 急性冠脉综合征, 急诊介入, 残粒脂蛋白-胆固醇, 主要心血管不良事件, 依折麦布

Abstract: AIM: To investigate the effect of ezetimibe combined with statins on residual lipoprotein-cholesterol (RLP-C) levels and major cardiovascular adverse events (MACE) in patients with acute coronary syndrome (ACS) after emergency intervention (PCI).  METHODS: A total of 90 hospitalized patients with ACS and undergoing emergency PCI were randomly divided into two groups: 48 patients in the control group received atorvastatin, and 42 patients in the study group were additionally treated with ezetimibe. RLP-C level before and after treatment was detected. The occurrence of MACE events and adverse drug events during the treatment were obtained through regular follow-up. RESULTS: Compared with the control group, the level of RLP-C in the study group was significantly decreased (P<0.05), the incidence of MACE were significantly decreased (P<0.05), and adverse drug events were not increased. CONCLUSION: The combination therapy of ezedemibe and statins can reduce RLP-C level and MACE in ACS patients undergoing emergency PCI with less adverse reactions, which is worthy of promotion and application.

Key words: acute coronary syndrome, emergency interventional treatment, residual lipoprotein, major adverse cardiac event, ezetimide

中图分类号: